Patent US5328955A successfully refreshed from Google Patents.
US5328955A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Collagen-polymer conjugates
Assignee: Surgical Specialties US Corp
•
Filing: 1992-07-30
•
Granted: 1994-07-12
•
Expires: 2012-07-30
Abstract
Abstract Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living being for the purpose of providing soft tissue augmentation. Once in place, the particles rehydrate and expand in size five fold or more.
Inventors
- 👤 Woonza Rhee
- 👤 Donald G. Wallace
- 👤 Alan S. Michaels
- 👤 Ramon A. Burns, Jr.
- 👤 Louis Fries
- 👤 Frank DeLustro
- 👤 Hanne Bentz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:02
CPC Classifications
C; C08; C08L; C08L89/00; C08L89/04; C08L89/06; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K47/61; A61K47/62; A61K47/64; A61K47/6435; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/225; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0033; A61L27/00; A61L27/14; A61L27/18; A61L27/20; A61L27/22; A61L27/24; A61L27/26; A61L27/28; A61L27/34; A61L27/40; A61L27/44; A61L27/50; A61L27/54; A61L29/00; A61L29/04; A61L29/043; A61L29/044; A61L29/045; A61L29/06; A61L29/14; A61L29/16; A61L31/00; A61L31/04; A61L31/041; A61L31/042; A61L31/043; A61L31/044; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61P; A61P17/00; A61P43/00; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K14/78; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0069; C08B37/0072; C08H; C08H1/00; C08H1/06; C09; C09J; C09J189/00; C09J189/04; C09J189/06; G; G02; G02B; G02B1/00; G02B1/04; G02B1/041; G02B1/043; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2310/00; A61F2310/00005; A61F2310/00365; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/426; A61L2300/60; A61L2300/62; A61L2300/80; A61L2300/802; A61L2430/00; A61L2430/16; C08L2666/00; C08L2666/02; Y; Y10; Y10S; Y10S525/00; Y10S525/937
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
16 words
A conjugate comprising collagen chemically conjugated by an ether bond to a synthetic nonimmunogenic hydrophilic polymer.
Claim 2
Dependent Claim
16 words
A conjugate comprising collagen chemically conjugated by an ether bond to a synthetic nonimmunogenic hydrophilic polymer.
Claim 3
Dependent Claim
16 words
The conjugate of claim 1, wherein the synthetic hydrophilic polymer is a difunctional activated polyethylene glycol.
Claim 4
Dependent Claim
16 words
The conjugate of claim 2, wherein the polymer is monomethylated polyethylene glycol activated at each end.
Claim 5
Dependent Claim
34 words
The conjugate of claim 1, wherein the conjugate has the following general structural formula: collagen-HN--OH--(CH.sub.2).sub.n --O-PEG-O--(CH.sub.2).sub.n --CO--NH-collagen wherein n is an integer selected from the group consisting of 0, 1, 2, 3, or 4.
Claim 6
Dependent Claim
41 words
The composition of claim 1, wherein the collagen is selected from the group consisting of type I, type II and type III collagen and the polymer is polyethylene glycol having a weight average molecular weight of about 100 to about 20,000.
Claim 7
Dependent Claim
20 words
The composition of claim 5 wherein said synthetic hydrophilic polymer is bound to an available lysine residue on said collagen.
Claim 8
Dependent Claim
24 words
The composition of claim 6 wherein the ratio of collagen molecules to polymer molecules is in the range of about 1:1 to about 1:20.
Claim 9
Dependent Claim
12 words
The composition of claim 6 wherein said atelopeptide collagen is fibrillar collagen.
Claim 10
Dependent Claim
21 words
The conjugate of claim 1, wherein the collagen is atelopeptide collagen and further comprising: a therapeutically effective amount of a cytokine.
Claim 11
Dependent Claim
67 words
The conjugate of claim 9 wherein the cytokine is selected from the group consisting of epidermal growth factor, transforming growth factor-α, transforming growth factor-β, transforming growth factor-β2, platelet-derived growth factor-AA, platelet-derived growth factor-AB, platelet-derived growth factor-BB, acidic fibroblast growth factor, basic fibroblast growth factor, connective tissue activating peptide, β-thromboglobulin, insulin-like growth factors, tumor necrosis factor, interleukine, colony stimulating factors, erythropoietin, nerve growth factor, interferons, and osteogenic factors.
Claim 12
Dependent Claim
26 words
The conjugate of claim 10, wherein the cytokine is selected from the group consisting of transforming growth factor-β, transforming growth factor-β1, transforming growth factor-β2, and erythropoietin.
Claim 13
Dependent Claim
16 words
The conjugate of claim 1, wherein the synthetic hydrophilic polymer is a succinimidyl monomethyl-polyethylene glycol glutarate.
Claim 14
Dependent Claim
33 words
The conjugate of claim 1, wherein the collagen is atelopeptide collagen and further comprising: a sufficient amount of a fluid pharmaceutically acceptable carrier to render the composition containing the conjugate flowable and injectable.
Claim 15
Dependent Claim
23 words
The conjugate of claim 1, wherein the polymer is monomethyl-polyethylene glycol having a weight average molecular weight of about 1,900 to about 8,000.
Claim 16
Dependent Claim
32 words
The conjugate of claim 1, wherein the synthetic hydrophilic non-immunogenic polymer has the following structural formula: ##STR8## wherein n is selected from the group consisting of 0, 1, 2, 3 and 4.
Claim 17
Dependent Claim
17 words
The conjugate of claim 1, wherein the synthetic, hydrophilic, non-immunogenic polymer has the following structural formula: ##STR9##
Claim 18
Dependent Claim
17 words
The conjugate of claim 1, wherein the synthetic, hydrophilic, non-immunogenic polymer has the following structural formula: ##STR10##
Claim 19
Dependent Claim
32 words
The conjugate of claim 1, wherein the synthetic, hydrophilic, non-immunogenic polymer has the following structural formula: ##STR11## wherein n is selected from the group consisting of 0, 1, 2, 3 and 4.
Claim 20
Dependent Claim
28 words
The conjugate of claim 1 wherein said composition comprises about 10 to about 100 mg/mL collagen and about 0.1 to about 30% synthetic hydrophilic polymer having reactive groups.
Claim 21
Dependent Claim
28 words
The conjugate of claim 19, wherein said composition comprises about 30 to about 80 mg/mL collagen and about 0.3 to about 10% synthetic hydrophilic polymer having reactive groups.
Claim 22
Dependent Claim
11 words
The conjugate of claim 1 wherein the collagen comprises fibrillar collagen.
Claim 23
Dependent Claim
11 words
The conjugate of claim 1 wherein the collagen comprises non-fibrillar collagen.
Claim 24
Dependent Claim
50 words
The conjugate of claim 1 further comprising a suitable particulate material selected from the group consisting of fibrillar, crosslinked collagen, gelatin beads, polytetrafluoroethylene beads, silicone rubber beads, hydrogel beads, silicon carbide beads, glass beads, calcium carbonate particles, hydroxyapatite particles, tricalcium phosphate particles, or mixtures of hydroxyapatite and tricalcium phosphate particles.
Claim 25
Dependent Claim
41 words
The conjugate of claim 1, further comprising a particulate material selected from the group consisting of hydroxyapatite particles, tricalcium phosphate particles, or mixtures of hydroxyapatite and tricalcium phosphate particles having an average diameter of about 1 to 20 microns in diameter.
Claim 26
Dependent Claim
13 words
The conjugate as claimed in claim 1, wherein the collagen is atelopeptide collagen.
References Cited (Backward Citations)
US3619371A
Cited
US3788948A
Cited
US3876501A
Cited
US4055635A
Cited
US4179337A
Cited
US3960830A
Cited
US3949073A
Cited
US4088538A
Cited
US4488911A
Cited
US4002531A
Cited
US4192021A
Cited
US4261973A
Cited
US4301144A
Cited
US4563490A
Cited
US4314380A
Cited
US4415665A
Cited
US4414147A
Cited
US4412989A
Cited
US4451568A
Cited
US4357274A
Cited
US4495285A
Cited
US4495285B1
Cited
US4424208A
Cited
US4582640A
Cited
EP0098110A2
Cited
US4737544A
Cited
WO1984001106A1
Cited
US4592864A
Cited
US4496689A
Cited
US4678468A
Cited
US4687820A
Cited
US4557764A
Cited
US4563350A
Cited
US4935465A
Cited
US4689399A
Cited
US4732863A
Cited
US4642117A
Cited
US4828563A
Cited
US4766106A
Cited
WO1987004078A1
Cited
EP0247860A2
Cited
US4745180A
Cited
US4979959A
Cited
US4847325A
Cited
US5162430A
Cited
US5201764A
Cited
JPH04227265A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-11 | 1998-01-10 | 1998-07-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-11 | 2002-01-10 | 2002-07-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-11 | 2006-01-10 | 2006-07-12 | $7700.00 | Window Closed / Lapsed |